John Frame, DO
Family Medicine · South Charleston, WVNPI 1699799015
Payments from drug & device makers
Across 559 payments — averaging $14.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$1K
- Lilly USA, LLC$1K
- AbbVie$882
- Amgen$563
- Boehringer Ingelheim$399
- plus $3K from 29 others
What the payments were for
- Food & beverage$8,034100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 104 | $1,309 |
| AstraZeneca | 57 | $1,055 |
| Lilly USA, LLC | 78 | $1,029 |
| AbbVie(2 entities) | 55 | $882 |
| Amgen(2 entities) | 50 | $563 |
| Boehringer Ingelheim | 30 | $399 |
| Merck | 22 | $317 |
| Novartis | 21 | $307 |
| Dexcom, Inc. | 19 | $303 |
| GSK | 15 | $220 |
| Amarin Pharma, Inc. | 14 | $203 |
| Exact Sciences | 10 | $166 |
| Kowa Pharmaceuticals America, Inc. | 14 | $159 |
| Pfizer | 8 | $153 |
| Johnson & Johnson | 9 | $133 |
| Bayer | 8 | $120 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $91 |
| Phathom Pharmaceuticals, Inc. | 5 | $77 |
| Teva Pharmaceuticals USA, Inc. | 5 | $76 |
| Sanofi-aventis U.S. LLC | 5 | $75 |
| Biohaven Pharmaceuticals, Inc. | 3 | $50 |
| Esperion Therapeutics, Inc. | 3 | $41 |
| Inspire Medical Systems, Inc. | 1 | $37 |
| Scynexis, Inc. | 1 | $33 |
| Eisai Inc. | 2 | $32 |
| Sunovion Pharmaceuticals Inc. | 2 | $29 |
| Lexicon Pharmaceuticals, Inc. | 2 | $29 |
| Arbor Pharmaceuticals, Inc. | 2 | $28 |
| Abbott | 2 | $28 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Incyte Corporation | 1 | $16 |
| Heartflow, Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
How this compares
$8,034 in reported general payments places this provider in the 90th percentile of 843 family medicine providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 123 | $136,290 |
| EliquisApixaban | 84 | $112,426 |
| JardianceEmpagliflozin | 73 | $97,733 |
| TrulicityDulaglutide | 73 | $95,868 |
| FarxigaDapagliflozin Propanediol | 84 | $87,559 |
| JanuviaSitagliptin Phosphate | 45 | $62,397 |
| XareltoRivaroxaban | 27 | $38,387 |
| RybelsusSemaglutide | 19 | $34,934 |
| MounjaroTirzepatide | 26 | $26,750 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $12,900 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 62 | $11,320 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 11 | $9,345 |
| BelsomraSuvorexant | 17 | $7,352 |
| Ezetimibe | 314 | $7,145 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $7,099 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,309 | $171,224142 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,029 | $122,61799 claims |
| PfizerEliquis | $153 | $112,42684 claims |
| Boehringer IngelheimJardiance | $399 | $97,73373 claims |
| AstraZenecaFarxiga | $1,055 | $87,55984 claims |
| MerckJanuvia, Belsomra | $317 | $69,74962 claims |
| Johnson & JohnsonXarelto | $133 | $38,38727 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $75 | $9,34511 claims |
| AbbVieSynthroid | $882 | $4,01170 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 843 family medicine providers in West Virginia.
Other family medicine in South Charleston
- Julie DetempleSouth Charleston$129K
- Kenneth AdkinsSouth Charleston$17K
- Chad TurnerSouth Charleston$11K
- Michelle BurdetteSouth Charleston$9K
- Howard LaffertySouth Charleston$8K
- Wilbur SineMorgantown$179K
- Dorian WilliamsMorgantown$169K
- Clemente DiazRichwood$127K
- John CornellHuntington$94K
- Mark CucuzzellaHarpers Ferry$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.